AstraZeneca

Baroness Chakrabarti Excerpts

Thursday 6th February 2025 Lords Chamber

[Lord Vallance of Balham (Lab)]

I thank the noble Lord—that is the first time I have been called complacent about vaccines. There is a lot going on: the Moderna investment in a new facility at Harwell; the BioNTech investment; the recent announcement of £60 million by GSK with Oxford; and there is a review of all the vaccine facilities across the country. It is absolutely essential to get this right, as the noble Lord has said, for future pandemic preparedness, as it is a key area. AstraZeneca remains, of course, with its major R&D base in this country, and I will be speaking to it again shortly.

[Baroness Chakrabarti (Lab)]

My Lords, I would call my noble friend the Minister a very dedicated public servant and not a bit complacent. Does he agree that a number of pharmaceutical companies, not least AstraZeneca, have benefited a great deal over the years from UK investment, including in universities and including through the purchasing power of the NHS, which is not inconsiderable? What do the Government plan to do to introduce an element of contingency into those relationships? Have the Government considered perhaps even their own state manufacturing capacity?

[Lord Vallance of Balham (Lab)]

I thank my noble friend for her question. The UK is fortunate to have two very large pharmaceutical companies in this land, and we have many biotechs starting up as a result, because many of the people in those biotechs were trained in the big companies. As my noble friend quite rightly points out, the relationship with the NHS is important. All of these things create an ecosystem for life sciences investment which we are very keen to continue. The history of state-run manufacturing facilities is not one that generally leads to advanced manufacturing and efficiency.